Free Trial

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Rhythm Pharmaceuticals logo
$89.00 +23.86 (+36.63%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$87.52 -1.48 (-1.66%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Key Stats

Today's Range
$75.01
$89.05
50-Day Range
$56.79
$89.00
52-Week Range
$40.61
$89.05
Volume
4.79 million shs
Average Volume
575,534 shs
Market Capitalization
$5.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.71
Consensus Rating
Buy

Company Overview

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

RYTM MarketRank™: 

Rhythm Pharmaceuticals scored higher than 70% of companies evaluated by MarketBeat, and ranked 285th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rhythm Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Rhythm Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rhythm Pharmaceuticals is -31.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rhythm Pharmaceuticals is -31.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rhythm Pharmaceuticals has a P/B Ratio of 254.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Rhythm Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.97% of the float of Rhythm Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Rhythm Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rhythm Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.97% of the float of Rhythm Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving.
  • News Sentiment

    Rhythm Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Rhythm Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    9 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,599,572.00 in company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.

  • Read more about Rhythm Pharmaceuticals' insider trading history.
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

RYTM Stock Analysis - Frequently Asked Questions

Rhythm Pharmaceuticals' stock was trading at $55.98 on January 1st, 2025. Since then, RYTM stock has increased by 59.0% and is now trading at $89.00.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.12. The firm's revenue for the quarter was up 25.9% on a year-over-year basis.
Read the conference call transcript
.

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals' top institutional shareholders include Harbor Capital Advisors Inc. (0.14%) and E. Ohman J or Asset Management AB (0.01%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, William T Roberts, Jennifer Kayden Lee, Jennifer Chien, Alastair Garfield, Lynn A Tetrault, Jennifer L Good and Christopher Paul German.
View institutional ownership trends
.

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/07/2025
Today
7/09/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RYTM
CIK
1649904
Employees
140
Year Founded
N/A

Price Target and Rating

High Price Target
$95.00
Low Price Target
$63.00
Potential Upside/Downside
-10.4%
Consensus Rating
Buy
Rating Score (0-4)
3.07
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$260.60 million
Net Margins
-123.26%
Pretax Margin
-123.19%

Debt

Sales & Book Value

Annual Sales
$136.86 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
254.29

Miscellaneous

Free Float
59,740,000
Market Cap
$5.66 billion
Optionable
Optionable
Beta
2.26
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:RYTM) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners